About the Company
evolus, inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the united states. it offers jeuveau, a proprietary 900 kilodalton purified botulinum toxin type a formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. the company was founded in 2012 and is headquartered in newport beach, california.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $EOLS News
Does Evolus, Inc. (EOLS) Have the Potential to Rally 63.24% as Wall Street Analysts Expect?
Shares of Evolus, Inc. (EOLS) have gained 5% over the past four weeks to close the last trading session at $14.09, but there could still be a solid upside left in the stock if short-term price targets ...
Analyst Estimates: Here's What Brokers Think Of Evolus, Inc. (NASDAQ:EOLS) After Its Full-Year Report
Last week, you might have seen that Evolus, Inc. ( NASDAQ:EOLS ) released its yearly result to the market. The ...
Evolus Reports Pricing Of $50 Mln Underwritten Offering Of Common Stock
Evolus, Inc. (EOLS) announced the pricing of the underwritten offering of 3,554,000 shares of its common stock at $14.07 per ...
Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock
Evolus intends to use the net proceeds of the offering to continue to fund the growth of Jeuveau ®, launch activities for Evolysse™, potential business development opportunities and general corporate ...
Evolus, Inc. (NASDAQ:EOLS) Q4 2023 Earnings Call Transcript
Q4 2023 Earnings Call March 7, 2024 Evolus, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the ...
Evolus Poised for Growth: Buy Rating Affirmed with $25 Price Target Amid Profitability Forecast and Competitive Market Positioning
Leerink Partners analyst Marc Goodman has reiterated their bullish stance on EOLS stock, giving a Buy rating on March 8. Marc Goodman has ...
Evolus Announces Results from European Head-to-Head Filler Trial
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, ...
Evolus Reports Pricing Of $50 Mln Underwritten Offering Of Common Stock
(RTTNews) - Monday, Evolus, Inc. (EOLS) announced the pricing of the underwritten offering of 3,554,000 shares of its common stock at $14.07 per share, matching the closing price on Friday ...
Evolus, Inc. (EOLS) Q4 2023 Earnings Call Transcript
Good afternoon, everyone, and thank you for standing by. Welcome to Evolus' Fourth Quarter and Full Year 2023 Earnings Conference Call. As a reminder, today's conference is being recorded and ...
Loading the latest forecasts...